SCHEMBL21761868

SCHEMBL21761868

COc1cc(OC)c(Cl)c(-c2cc3cnc(SC)nc3nc2Cl)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 2/20 0.36
FGFR1 P11362 6/20 0.36
AURKA O14965 1/20 0.33
KDR P35968 1/20 0.33
AURKB Q96GD4 1/20 0.33
MAPT P10636 5/20 0.33
TDP1 Q9NUW8 3/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
PDE4B Q07343 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22396654 0.88 FGFR1 (0.42) FGFR4FGFR1
SCHEMBL21761869 0.84 FGFR1 (0.38) FGFR4FGFR1MAPTKDM4EPDE4B
SCHEMBL21783951 0.84 MEN1 (0.36) FGFR4FGFR1KDRMEN1KMT2A
SCHEMBL19817005 0.81 FGFR1 (0.39) FGFR1AURKAKDRAURKBMAPT
SCHEMBL23328706 0.78 FGFR1 (0.50) FGFR4FGFR1AURKAKDRAURKB
SCHEMBL19817044 0.77 FGFR1 (0.50) FGFR4FGFR1AURKAKDRAURKB
SCHEMBL29536557 0.77 FGFR1 (0.50) FGFR4FGFR1AURKAKDRAURKB
SCHEMBL16246372 0.76 FGFR4 (0.42) FGFR4FGFR1MAPTKDM4EPDE4B
SCHEMBL16246197 0.76 CCNT1 (0.34) FGFR4FGFR1MAPTKDM4EPDE4B
SCHEMBL30089813 0.76 FGFR4 (0.42) FGFR4FGFR1MAPTKDM4EPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed
WO-2020038458-A1 CLASS OF FUSED RING TRIAZOLE COMPOUND, PREPARATION METHOD, AND USE 如东凌达生物医药科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 FGFR4 2/4885FGFR1 1/4885AURKA 600/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 FGFR4 2/4885FGFR1 1/4885AURKA 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.